Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie Obserwacyjne Foslewodopy/Foskarbidopy w Rzeczywistych Warunkach Klinicznych w Celu Oceny Wyników Jakości Życia u Dorosłych Uczestników We Wcześniejszym Etapie Zaawansowanej Choroby Parkinsona (PUCCINI)

6 listopada 2026 zaktualizowane przez: AbbVie

Globalne badanie oparte na rzeczywistych dowodach dotyczące skuteczności i bezpieczeństwa/tolerancji foslewodopy/foskarbidopy u pacjentów we wcześniejszym etapie zaawansowanej choroby Parkinsona

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.

There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being

Przegląd badań

Status

Rekrutacyjny

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

100

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • City of Zagreb
      • Grad Zagreb, City of Zagreb, Chorwacja, 10000
        • Rekrutacyjny
        • Klinicka Bolnica Dubrava /ID# 278408
    • Primorje-Gorski Kotar County
      • Rijeka, Primorje-Gorski Kotar County, Chorwacja, 51000
        • Rekrutacyjny
        • Klinicki Bolnicki Centar Rijeka /ID# 278277
    • Barcelona
      • Sant Joan Despí, Barcelona, Hiszpania, 08970
        • Rekrutacyjny
        • Hospital de Sant Joan Despi Moises Broggi /ID# 276895
      • Jerusalem, Izrael, 91120
        • Rekrutacyjny
        • Hadassah Medical Center-Hebrew University /ID# 276211
    • Jerusalem
      • Jerusalem, Jerusalem, Izrael, 91031
        • Rekrutacyjny
        • Shaare Zedek Medical Center /ID# 276209
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Izrael, 5265601
        • Rekrutacyjny
        • The Chaim Sheba Medical Center /ID# 276210
      • Tel Aviv, Tel Aviv, Izrael, 6423906
        • Rekrutacyjny
        • Tel Aviv Sourasky Medical Center /ID# 276212
      • Kanagawa, Japonia, 231-0063
        • Rekrutacyjny
        • Noge General Medicine and Neurology /ID# 280741
      • Tokushima, Japonia, 770-0852
        • Rekrutacyjny
        • Itsuki Hospital /ID# 280743
      • Tokyo, Japonia, 202-0004
        • Rekrutacyjny
        • Miwa Internal Medicine Clinic /ID# 280740
    • Saitama
      • Iruma-gun, Saitama, Japonia, 3500495
        • Rekrutacyjny
        • Saitama Medical University Hospital /ID# 280624
    • Tokyo
      • Bunkyo-ku, Tokyo, Japonia, 113-8431
        • Rekrutacyjny
        • Juntendo University Hospital /ID# 280623
    • Ontario
      • Toronto, Ontario, Kanada, M5T 2S8
        • Rekrutacyjny
        • Toronto Western Hospital /ID# 278384
    • Quebec
      • Sherbrooke, Quebec, Kanada, J1H 5N4
        • Rekrutacyjny
        • CIUSSS de l Estrie - CHUS /ID# 278379
      • Guaynabo, Portoryko, 00969
        • Rekrutacyjny
        • Centro Internacional De Mercadeo /ID# 276088
      • Brasov, Rumunia, 500326
        • Rekrutacyjny
        • Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499
    • Bucharest
      • Bucharest, Bucharest, Rumunia, 022328
        • Rekrutacyjny
        • Fundeni Clinical Institute /ID# 277490
    • Iaşi
      • Iași, Iaşi, Rumunia, 700620
        • Rekrutacyjny
        • Arcadia Spitale Si Centre Medicale /Id# 277525
    • Timiș County
      • Timișoara, Timiș County, Rumunia, 300724
        • Rekrutacyjny
        • Neurotim Med /ID# 277500
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33486
        • Rekrutacyjny
        • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190
      • Tampa, Florida, Stany Zjednoczone, 33613
        • Rekrutacyjny
        • University of South Florida- Neuroscience Institute /ID# 278562
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28207-1196
        • Rekrutacyjny
        • Novant Health /ID# 278567
    • Texas
      • Georgetown, Texas, Stany Zjednoczone, 78628
        • Rekrutacyjny
        • Texas Movement Disorder Specialists /ID# 278565
      • Newcastle upon Tyne, Zjednoczone Królestwo, NE3 3HD
        • Rekrutacyjny
        • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752
    • Devon
      • Plymouth, Devon, Zjednoczone Królestwo, PL6 8DH
        • Rekrutacyjny
        • University Hospitals Plymouth NHS Trust /ID# 284977
    • Hammersmith and Fulham
      • London, Hammersmith and Fulham, Zjednoczone Królestwo, W6 8RF
        • Rekrutacyjny
        • Charing Cross Hospital /ID# 284211

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 69 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.

Opis

Inclusion Criteria:

  • Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
  • A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
  • Adult male or female between 18 and 69 years of age
  • Disease duration (time since diagnosis) <10 years
  • Time since motor fluctuations started ≤5 years
  • H&Y Stage <3 in best "on"
  • "off" time of ≤ 4.5 hours per day
  • Naïve to LDp/CDp
  • Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
  • Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
  • Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
  • Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered

Exclusion Criteria:

  • History of any condition included in the contraindications section of the approved local Foslevodopa/Foscarbidopa (LDp/CDp) label in the participating country
  • History of treatment with any Device-Aided Therapy (DAT), such as Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa/Carbidopa Intestinal Gel (LCIG)/ Carbidopa/Levodopa Enteral Suspension (CLES), Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG)
  • Mini-Mental State Examination (MMSE) score <24
  • Participation in a concurrent investigational or observational clinical trial
  • Lack of motivation/insufficient language skills to complete the study questionnaires
  • History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis). In case of temporary affections like recent sunburn or open wounds, or in case of permanent affections like acne, scar tissue, tattoo, branding, or colorations, the participant should not be included if the Investigator considers these as interfering with infusion of study drug or study assessments.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Foslevodopa/Foscarbidopa

Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore
Ramy czasowe: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores
Ramy czasowe: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score
Ramy czasowe: Up to approximately 6 months

The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score
Ramy czasowe: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe)

Up to approximately 6 months
Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Ramy czasowe: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)
Ramy czasowe: Up to approximately 6 months

The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening.

Up to approximately 6 months
Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Ramy czasowe: Up to approximately 6 months

The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement.

Up to approximately 6 months
Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
Ramy czasowe: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.
Ramy czasowe: Up to approximately 6 months

The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.
Ramy czasowe: Up to approximately 6 months

Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe.

Up to approximately 6 months
Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire
Ramy czasowe: Up to approximately 6 months

The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse.

Up to approximately 6 months
Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.
Ramy czasowe: Up to approximately 6 months

The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse.

Up to approximately 6 months

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.
Ramy czasowe: Up to approximately 6 months

Measured by dedicated questionnaire.

Up to approximately 6 months
Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12
Ramy czasowe: Up to approximately 6 months

The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]).

Up to approximately 6 months
Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale
Ramy czasowe: Up to approximately 6 months

The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy).

Up to approximately 6 months
Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)
Ramy czasowe: Up to approximately 6 months

Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident.

Up to approximately 6 months
Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale
Ramy czasowe: Up to approximately 6 months

The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living.

Up to approximately 6 months
Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)
Ramy czasowe: Up to approximately 6 months

Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options.

Up to approximately 6 months
Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
Ramy czasowe: Up to approximately 6 months

The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable).

Up to approximately 6 months
Healthcare Resource Utilization (HRU)
Ramy czasowe: Up to approximately 6 months

Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists.

Up to approximately 6 months
Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)
Ramy czasowe: Up to approximately 6 months

Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6

Up to approximately 6 months
Questionnaire to investigate the practicalities of the infusion system
Ramy czasowe: Up to approximately 6 months

Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments).

Up to approximately 6 months
Number of Participants with Adverse Events (AEs)
Ramy czasowe: Up to approximately 6 months

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to approximately 6 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: ABBVIE INC., AbbVie

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

3 sierpnia 2026

Zakończenie podstawowe (Szacowany)

1 października 2027

Ukończenie studiów (Szacowany)

1 października 2027

Daty rejestracji na studia

Pierwszy przesłany

10 listopada 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2025

Pierwszy wysłany (Rzeczywisty)

13 listopada 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

10 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj